| 000 | 01838 a2200541 4500 | ||
|---|---|---|---|
| 005 | 20250517171328.0 | ||
| 264 | 0 | _c20180725 | |
| 008 | 201807s 0 0 eng d | ||
| 022 | _a1365-2516 | ||
| 024 | 7 |
_a10.1111/hae.13324 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aCollins, P W | |
| 245 | 0 | 0 |
_aPharmacokinetics, safety and efficacy of a recombinant factor IX product, trenonacog alfa in previously treated haemophilia B patients. _h[electronic resource] |
| 260 |
_bHaemophilia : the official journal of the World Federation of Hemophilia _cJan 2018 |
||
| 300 |
_a104-112 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Randomized Controlled Trial | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aArea Under Curve |
| 650 | 0 | 4 |
_aBlood Coagulation Factor Inhibitors _xblood |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 |
_aFactor IX _xadverse effects |
| 650 | 0 | 4 | _aHalf-Life |
| 650 | 0 | 4 |
_aHeadache _xetiology |
| 650 | 0 | 4 |
_aHemophilia B _xdrug therapy |
| 650 | 0 | 4 |
_aHemorrhage _xprevention & control |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aROC Curve |
| 650 | 0 | 4 |
_aRecombinant Proteins _xpharmacokinetics |
| 650 | 0 | 4 | _aSeverity of Illness Index |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aQuon, D V K | |
| 700 | 1 | _aMakris, M | |
| 700 | 1 | _aChowdary, P | |
| 700 | 1 | _aKempton, C L | |
| 700 | 1 | _aApte, S J | |
| 700 | 1 | _aRamanan, M V | |
| 700 | 1 | _aHay, C R M | |
| 700 | 1 | _aDrobic, B | |
| 700 | 1 | _aHua, Y | |
| 700 | 1 | _aBabinchak, T J | |
| 700 | 1 | _aGomperts, E D | |
| 773 | 0 |
_tHaemophilia : the official journal of the World Federation of Hemophilia _gvol. 24 _gno. 1 _gp. 104-112 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/hae.13324 _zAvailable from publisher's website |
| 999 |
_c27490793 _d27490793 |
||